VYNE Therapeutics (VYNE) said Friday that the FDA has placed a clinical halt on its phase 1b trial of its psoriasis drug due to signs of testicular toxicity found in a recent animal study.
The company also said suspended new enrollment and patient treatment in the study and said it plans to cooperate closely with regulators to lift the hold.
VYNE noted that no serious side effects have been observed in human participants enrolled so far.
The FDA action does not impact VYNE's phase 2b trial of repibresib gel, which involves a separate drug candidate, the company said.
Shares of VYNE were down more than 30% in recent Friday premarket activity.
Price: 1.31, Change: -0.57, Percent Change: -30.11
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。